Replies to post #2044 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

These 6-year Baraclude data add substance to the notion that patients should be treated for chronic HBV even when they are asymptomatic:

http://biz.yahoo.com/bw/081102/20081102005040.html

Although treatment for asymptomatic chronic HBV lowers the risk of liver failure and liver cancer, such a treatment protocol has never caught on in a big way. This is a potential growth driver for all HBV drugs if such guidelines were to be formally adopted.